CN104768553A - 用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物 - Google Patents

用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物 Download PDF

Info

Publication number
CN104768553A
CN104768553A CN201380057293.0A CN201380057293A CN104768553A CN 104768553 A CN104768553 A CN 104768553A CN 201380057293 A CN201380057293 A CN 201380057293A CN 104768553 A CN104768553 A CN 104768553A
Authority
CN
China
Prior art keywords
oxo
benzyl
methyl
ylmethoxy
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380057293.0A
Other languages
English (en)
Chinese (zh)
Inventor
M.弗里泽-哈米姆
F.布拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN104768553A publication Critical patent/CN104768553A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380057293.0A 2012-11-02 2013-10-04 用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物 Pending CN104768553A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12007494.3 2012-11-02
EP12007494 2012-11-02
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (1)

Publication Number Publication Date
CN104768553A true CN104768553A (zh) 2015-07-08

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380057293.0A Pending CN104768553A (zh) 2012-11-02 2013-10-04 用于治疗肝细胞癌(hcc)的6-氧代-1,6-二氢-哒嗪衍生物

Country Status (26)

Country Link
US (1) US20150283137A1 (cg-RX-API-DMAC7.html)
EP (1) EP2914264B1 (cg-RX-API-DMAC7.html)
JP (1) JP6255028B2 (cg-RX-API-DMAC7.html)
KR (1) KR102131588B1 (cg-RX-API-DMAC7.html)
CN (1) CN104768553A (cg-RX-API-DMAC7.html)
AR (1) AR093318A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013339823B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008279A2 (cg-RX-API-DMAC7.html)
CA (1) CA2890273C (cg-RX-API-DMAC7.html)
DK (1) DK2914264T3 (cg-RX-API-DMAC7.html)
ES (1) ES2646913T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211869A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171295T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035483T2 (cg-RX-API-DMAC7.html)
IL (1) IL238536B (cg-RX-API-DMAC7.html)
LT (1) LT2914264T (cg-RX-API-DMAC7.html)
MX (1) MX354518B (cg-RX-API-DMAC7.html)
NO (1) NO2914264T3 (cg-RX-API-DMAC7.html)
PL (1) PL2914264T3 (cg-RX-API-DMAC7.html)
PT (1) PT2914264T (cg-RX-API-DMAC7.html)
RS (1) RS56485B1 (cg-RX-API-DMAC7.html)
RU (1) RU2650679C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201503214YA (cg-RX-API-DMAC7.html)
SI (1) SI2914264T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014067610A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503924B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555053A (zh) * 2019-10-14 2022-05-27 欧拉泰克治疗有限责任公司 治疗乳腺癌的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002932B1 (pt) 2013-08-14 2021-02-23 Yugenkaisha Japan Tsusyo sistema de cultivo hidropônico
HRP20231548T1 (hr) * 2019-07-10 2024-03-15 Merck Patent Gmbh Farmaceutski pripravak

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272121A (zh) * 2009-01-08 2011-12-07 默克专利有限公司 3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐的新型多晶型物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272121A (zh) * 2009-01-08 2011-12-07 默克专利有限公司 3-(1-{3-[5-(1-甲基-哌啶-4-基甲氧基)-嘧啶-2-基]-苄基}-6-氧代-1,6-二氢-哒嗪-3-基)-苄腈盐酸盐的新型多晶型物及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555053A (zh) * 2019-10-14 2022-05-27 欧拉泰克治疗有限责任公司 治疗乳腺癌的方法
US12582628B2 (en) 2019-10-14 2026-03-24 Olatec Therapeutics, Inc. Methods for treating breast cancer

Also Published As

Publication number Publication date
MX2015005265A (es) 2015-07-17
MX354518B (es) 2018-03-08
RS56485B1 (sr) 2018-01-31
RU2015120692A (ru) 2016-12-27
JP2015536957A (ja) 2015-12-24
CA2890273A1 (en) 2014-05-08
ZA201503924B (en) 2020-11-25
DK2914264T3 (en) 2017-09-11
SG11201503214YA (en) 2015-05-28
EP2914264B1 (en) 2017-08-09
IL238536A0 (en) 2015-06-30
HK1211869A1 (en) 2016-06-03
EP2914264A1 (en) 2015-09-09
BR112015008279A2 (pt) 2017-07-04
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
PL2914264T3 (pl) 2017-12-29
AR093318A1 (es) 2015-05-27
HRP20171295T1 (hr) 2017-10-20
ES2646913T3 (es) 2017-12-18
RU2650679C2 (ru) 2018-04-17
KR102131588B1 (ko) 2020-07-08
LT2914264T (lt) 2017-11-10
NO2914264T3 (cg-RX-API-DMAC7.html) 2018-01-06
IL238536B (en) 2019-01-31
AU2013339823A1 (en) 2015-06-18
US20150283137A1 (en) 2015-10-08
WO2014067610A1 (en) 2014-05-08
AU2013339823B2 (en) 2018-01-04
HUE035483T2 (hu) 2018-05-02
CA2890273C (en) 2021-10-26
PT2914264T (pt) 2017-11-14
JP6255028B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
AU2013234767B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
AU2015360006B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
EP2914264B1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
US20190388423A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
EP2906294B1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor
CN105848658A (zh) 具有抗癌活性的6-氧代-1,6-二氢-哒嗪衍生物与吉非替尼的组合
CN105873591A (zh) 用于治疗肾细胞癌(rcc)的6-氧代-1,6-二氢-哒嗪衍生物
HK1227693A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211869

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211869

Country of ref document: HK